Ultrasonographic appearance of endometrium in postmenopausal breast cancer patients receiving tamoxifen

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 67, Issue 2, 1996, Pages 157-162

  Beşe, Tugan ^a,b   Kösebay, Derin ^a   Demirkiran, Fuat ^a   Arvas, Macit ^a   Beşe, Nuran ^a   Mandel, Nil ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Ortaklar Cad   (Turkey)

Author keywords

Endometrial histopathology; Tamoxifen; Ultrasonographic appearance

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0030218945     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/0301-2115(96)02456-6     Document Type: Article

References (21)

1. [1] Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Therap 1984; 25: 127-205.
2. [2] Jordan GV. Long term adjuvan tamoxifen therapy for breast cancer. Breast Cancer Res Treat 1990; 15: 125-136.
3. [3] Buchanan RB, Blamey RW, Durrent KR, et al. A randomized comparison of tamoxifen with surgical oophorectomy in prenenopausal patients with advanced breast cancer. J Clin Oncol 1986; 4: 1326-1330.
4. [4] Baum M, Brinkley DM, Dosset JA. Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer. Br J. Cancer 1988; 57: 608-611.
5. [5] Cohen I, Rosen DJD, Shapyra J, et al. Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymtomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994; 52: 185-190.
6. [6] Cohen I, Tepper R, Rosen DJD, et al. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies. Gynecol Oncol 1994; 55: 138-143.
7. [7] Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 1987; 2: 171-175.
8. [8] O'Neill E, Rodriguez Mojica W. Asymptomatic carcinoma of the endometrium in patient on adjunctive tamoxifen therapy for carcinoma of the breast. Bol Assoc Med P R 1992; 84: 74-77.
9. [9] Varner RE, Sparks JM, Cameron CD, Roberts LL, Soong SJ. Transvaginal sonograhpy of the endometrium in postmenopausal women. Obstet Gynecol 1991; 78: 195-199.
10. [10] Goldstein SR, Nachtigall M, Snyder JR, Nachtigall L. Endometrial assesment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol 1990; 163: 119-123.
11. [11] Nasri MN, Coast GJ. Correlation of ultrasound findigs and endometrial histopathology in postmenopausal women. Br J Obstet Gynecol 1989; 86: 1333-1338.
12. [12] Nasri MN, Shephard JH, Setchell ME, Lowe DG, Chard T. The role of vaginal scan in measurement of endometrial thickness in postmenopausal women. Br J Obstet Gynaecol 1991; 98: 470-475.
13. [13] Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 194; 47: 827-833.
14. [14] Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994; 343: 1318-1321.
15. [15] Lanhi E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in posmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81: 660-664.
16. [16] Cohen I, Altaras MM, Shapira J, Tepper R, Beyth Y. Postmenopausal tamoxifen treatment and endometrial pathology. Obstet Gynecol Survey 1994; 49: 823-829.
17. [17] Bissett D, Davis JA, George WD. Gynaecological monitoring during tamoxifen therapy. Lancet 1994; 344: 1244.
18. [18] Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994; 170: 447-451.
19. [19] Bornstein J, Auslender R, Paskal B, Gutterman E, Isakov D, Abramovici H. Diagnosis pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. J Reprod Med 1994; 734: 310-321.
20. [20] Anteby E, Yagel S, Zacut D, Palti Z, Hochner-Celnikier D. False sonographic appearance of endometrial neoplasia in postmenopausal women treated with tamoxifen. Lancet 1992; 34: 433-434.
21. [21] Granberg S, Wickland M, Karlsson B, et al. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991; 164: 47-52.